BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blumenstein I, Bock H, Weber C, Rambow A, Tacke W, Kihn R, Pfaff R, Orlemann S, Schaeffer R, Schröder O, Digna A, Hartmann F, Stein J. Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: A multicenter, prospective, internet-based study: . Inflammatory Bowel Diseases 2008;14:53-60. [DOI: 10.1002/ibd.20257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Bodger K. Cost Effectiveness of Treatments for Inflammatory Bowel Disease: . PharmacoEconomics 2011;29:387-401. [DOI: 10.2165/11584820-000000000-00000] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
2 Schnorbach MT, Kruis W. [Cost of illness of inflammatory bowel disease in Germany]. Z Gastroenterol 2021;59:1173-88. [PMID: 32869213 DOI: 10.1055/a-1174-0670] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther 2021;54:234-48. [PMID: 34114667 DOI: 10.1111/apt.16445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Haapamäki J, Tanskanen A, Roine RP, Blom M, Turunen U, Mäntylä J, Färkkilä MA, Arkkila PE. Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. Scand J Gastroenterol 2013;48:42-50. [PMID: 23163864 DOI: 10.3109/00365521.2012.743584] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
5 Hausmann J, Zabel K, Herrmann E, Schröder O. Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010;16:1195-202. [PMID: 19924799 DOI: 10.1002/ibd.21166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sin AT, Damman JL, Ziring DA, Gleghorn EE, Garcia-Careaga MG, Gugig RR, Hunter AK, Burgis JC, Bass DM, Park KT. Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis. Inflamm Bowel Dis 2015;21:1368-77. [PMID: 25839776 DOI: 10.1097/MIB.0000000000000374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Prenzler A, Bokemeyer B, von der Schulenburg J, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Health Econ 2011;12:273-83. [DOI: 10.1007/s10198-010-0281-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
8 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Bokemeyer B, Hardt J, Hüppe D, Prenzler A, Conrad S, Düffelmeyer M, Hartmann P, Hoffstadt M, Klugmann T, Schmidt C, Weismüller J, Mittendorf T, Raspe H. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis 2013;7:355-68. [PMID: 22503168 DOI: 10.1016/j.crohns.2012.02.014] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
10 Blumenstein I, Herrmann E, Filmann N, Zosel C, Tacke W, Bock H, Dignass A, Hartmann F, Zeuzem S, Stein J, Schröder O. Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. J Crohns Colitis 2011;5:203-10. [PMID: 21575882 DOI: 10.1016/j.crohns.2010.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
11 Wills ES, Jonkers DM, Savelkoul PH, Masclee AA, Pierik MJ, Penders J. Fecal microbial composition of ulcerative colitis and Crohn’s disease patients in remission and subsequent exacerbation. PLoS One. 2014;9:e90981. [PMID: 24608638 DOI: 10.1371/journal.pone.0090981] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
12 Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fde L, Moum B. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936-945. [PMID: 24572205 DOI: 10.1097/01.mib.0000442728.74340.fd] [Cited by in Crossref: 78] [Cited by in F6Publishing: 39] [Article Influence: 11.1] [Reference Citation Analysis]
13 Hueppe A, Langbrandtner J, Raspe H. Inviting patients with inflammatory bowel disease to active involvement in their own care: a randomized controlled trial. Inflamm Bowel Dis 2014;20:1057-69. [PMID: 24788217 DOI: 10.1097/MIB.0000000000000044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Kredel LI, Schneidereit O, Hoffmann JC, Siegmund B, Preiß JC. Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey. Int J Colorectal Dis 2019;34:431-40. [PMID: 30523398 DOI: 10.1007/s00384-018-3215-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]